T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Feunou, Pascal Feunou ^a,b,c   Bertout, Julie ^b,c,d   Locht, Camille ^a,b,c  

^a INSERM U1019   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIV LILLE   (France)

^d Molecular and Cellular Medicine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BPZE1 VACCINE; GAMMA INTERFERON; INTERLEUKIN 17; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BACTERIAL GROWTH; BACTERIAL STRAIN; BORDETELLA PARAPERTUSSIS; BORDETELLA PARAPERTUSSIS INFECTION; BORDETELLA PERTUSSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IN VITRO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; TH1 CELL; TH17 CELL; ANIMAL; ANTIBODY PRODUCTION; CROSS PROTECTION; DRUG SCREENING; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; T LYMPHOCYTE;

BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; MUS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; DRUG EVALUATION, PRECLINICAL; MICE; PERTUSSIS VACCINE; T-LYMPHOCYTES; VACCINES, ATTENUATED;

EID: 77956307858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010178     Document Type: Article

References (52)

1. Greenberg DP, von König CH, Heininger U (2005) Health burden of pertussis in infants and hildren. Pediatr Infect Dis J 24: S39-S43.
2. McIntyre P, Wood N (2009) Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis 22: 215-223.
3. Von König CH, Halperin S, Riffelmann M, Guiso N (2002) Pertussis of adults and infants. Lancet Infect Dis 2: 744-750.
4. Crowcroft NS, Stein C, Duclos P, Birmingham M (2003) How best to estimate the global burden of pertussis? Lancet Infect Dis 3: 423-418.
5. Edwards KM (2005) Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 24(Suppl.): S104-S108.
6. Storsaeter J, Wolter J, Locht C (2007) Pertussis vaccines. In Bordetella Molecular Microbiology. C Locht, editor Horizon Bioscience, Norfolk, UK. pp 245-288.
7. Jefferson T, Rudin M, DiPietrantonj C (2003) Systematic review of the effects of pertussis vaccines in children. Vaccine 21: 2003-2014.
8. Sato Y, Kimura M, Fukumi H (1984) Development of a pertussis component vaccine in Japan. Lancet 8369: 122-126.
9. Decker MD, Edwards KM (2000) Acellular pertussis vaccines. Pediatr Clin North Am 47: 309-335.
10. Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, et al. (1997) A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a forth dose in 15- to 20- months-old children. Pediatrics 100: 772-788.
11. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H (1997) Randomised controlled trial of two-component, three-component, and fivecomponent acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 334: 1569-1577.
12. Hellwig SM, van Spriel AB, Schellekens JF, Mooi FR, van de Winkel JG (2001) Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun 69: 4846-4850.
13. Letowska I, Hryniewicz W (2004) Epidemiology and characterization of Bordetella parapertussis strains isolated between 1995 and 2002 in and around Warsaw, Poland. Eur J Clin Microbiol Infect Dis 23: 499-501.
14. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, et al. (2003) Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 35: 32-40.
15. Mastrantonio P, Giuliano M, Stefanelli P, Sofia T, De Marzi L, et al. (1997) Bordetella parapertussis infections. Dev Biol Stand 89: 255-259.
16. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J (1998) Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 280: 635-637.
17. Bergfors E, Trollfors B, Taranger J, Lagergard T, Sundh V, et al. (1999) Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Int J Infect Dis 3: 140-146.
18. Heininger U, Stehr K, Schmitt-Grohe S, Lorenz C, Rost R, et al. (1994) Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 13: 306-309.
19. David S, van Furth R, Mooi FR (2004) Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine 22: 1892-1898.
20. Wolfe DN, Goebel EM, Bjornstad ON, Restif O, Harvill ET (2007) The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun 75: 4972-4979.
21. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, et al. (2006) Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2: e65.
22. Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, et al. (2008) Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 26: 5722-5727.
23. Mills KH (2001) Immunity to Bordetella pertussis. Microbes Infect 3: 655-677.
24. Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KH (1997) Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J Exp Med 186: 1843-1851.
25. Centers for Disease Control and Prevention (2004) Fatal case of unsuspected pertussis diagnosed from a blood culture-Minnesota, 2003. MMWR Morb Mortal Wkly Rep 53: 131-132.
26. Mills KH, Barnard A, Watkins J, Redhead K (1993) Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 61: 399-410.
27. Byrne P, McGuirk P, Todryk S, Mills KH (2004) Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur J Immunol 34: 2579-2588.
28. Kirimanjeswara GS, Mann PB, Harvill ET (2003) Role of antibodies in immunity to Bordetella infections. Infect Immun 71: 1719-1724.
29. Leef M, Elkins KL, Barbic J, Shahin RD (2000) Protective immunity to Bordetella pertussis requires both B cells and CD4 (+) T cells for key functions other than specific antibody production. J Exp Med 191: 1841-1852.
30. Menozzi FD, Mutombo R, Renauld G, Gantiez C, Hannah JH, et al. (1994) Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect Immun 62: 769-778.
31. Higgins SC, Jarnicki AG, Lavelle ED, Mills KHG (2006) TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17- producing T cells. J Immunol 177: 7980-7989.
32. Chen X, Howard OMZ, Oppenheim JJ (2007) Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J Immunol 178: 6123-6129.
33. McGuirk P, McCann C, Mills KH (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195: 221-231.
34. Mills KHG, Ryan M, Ryan E, Mahon BP (1998) A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66: 594-602.
35. Watanabe M, Nagai M (2004) Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti-infect Ther 2: 447-454.
36. Watanabe M, M Nagai (2001) Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect Immun 69: 6981-6986.
37. Goebel EM, Wolfe DN, Elder K, Stibitz S, Harvill ET (2008) O antigen protects Bordetella parapertussis from complement. Infect Immun 76: 1774-1780.
38. Mascart F, Verscheure V, Malfroot A, Hainaut M, Piérard D, et al. (2003) Bordetella pertussis infection in 2-months-old infants promotes type 1 T cell responses. J Immunol 170: 1504-1509.
39. Woolard MD, Hensley LL, Kahula TH, Frelinger JA (2008) Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun 76: 2651-2659.
40. Ma CS, Chew GYJ, Simpson N, Priyadarshi A, Wong M, et al. (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205: 1551-1557.
41. Page G, Sattler A, Kersten S, Thiel A, Radbruch A, et al. (2004) Plasma cell-like morphology of Th1-cytokine-producing cells associated with the of CD3 expression. Am J Path 164: 409-417.
42. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFb in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-prodicing T cells. Immunity 24: 179-189.
43. Annunziato F, Cosmi L, Stantarlasci V, Maggi L, Liotta L, et al. (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204: 1849-1861.
44. Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, et al. (2008) Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol 181: 4485-4494.
45. Nasso M, Fedele G, Spensieri F, Palazzo R, Costantino P, et al. (2009) Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10 dependent mechanisms. J Immunol 183: 1892-1899.
46. Fedele G, Nasso M, Stensieri F, Palazzo R, Frasca L, et al. (2008) Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human dendritic cell functions resulting in divergent prevalence of Th17-polarized responses. J Immunol 181: 208-216.
47. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132.
48. Dubin PJ, Kolls JK (2008) Th17 cytokines and mucosal immunity. Immunol Rev 226: 160-171.
49. Locht C, Geoffroy MC, Renauld G (1992) Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbrae share sequence similarities with the papC and papD gene families. EMBO J 11: 3175-3183.
50. Antoine R, Locht C (1990) Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun 58: 1518-1526.
51. Sekura RD, Fish F, Manckark CR, Meade B, Zhang YL (1983) Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem 258: 14647-14651.
52. Menozzi FD, Gantiez C, Locht C (1991) Interaction of Bordetella pertussis filamentous hemagglutinin with heparin. FEMS Microbiol Lett 78: 59-64.